These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 16934430)

  • 41. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.
    Rodríguez-Baño J; Picón E; Gijón P; Hernández JR; Ruíz M; Peña C; Almela M; Almirante B; Grill F; Colomina J; Giménez M; Oliver A; Horcajada JP; Navarro G; Coloma A; Pascual A;
    Clin Infect Dis; 2010 Jan; 50(1):40-8. PubMed ID: 19995215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CTX-M-1- and CTX-M-15-type beta-lactamases in clinical Escherichia coli isolates recovered from food-producing animals in France.
    Meunier D; Jouy E; Lazizzera C; Kobisch M; Madec JY
    Int J Antimicrob Agents; 2006 Nov; 28(5):402-7. PubMed ID: 17027237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
    Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
    J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital.
    Cassier P; Lallechère S; Aho S; Astruc K; Neuwirth C; Piroth L; Chavanet P
    Clin Microbiol Infect; 2011 Nov; 17(11):1746-51. PubMed ID: 20840333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15.
    Blanco M; Alonso MP; Nicolas-Chanoine MH; Dahbi G; Mora A; Blanco JE; López C; Cortés P; Llagostera M; Leflon-Guibout V; Puentes B; Mamani R; Herrera A; Coira MA; García-Garrote F; Pita JM; Blanco J
    J Antimicrob Chemother; 2009 Jun; 63(6):1135-41. PubMed ID: 19351692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M beta-lactamases.
    Lavigne JP; Blanc-Potard AB; Bourg G; Moreau J; Chanal C; Bouziges N; O'callaghan D; Sotto A
    Clin Microbiol Infect; 2006 Dec; 12(12):1199-206. PubMed ID: 17121626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CTX-M type extended spectrum beta-lactamases in Escherichia coli isolates from community acquired upper urinary tract infections at a university in the European part of Turkey.
    Celik AD; Yulugkural Z; Kuloglu F; Eroglu C; Torol S; Vahaboğlu H; Akata F
    J Microbiol Immunol Infect; 2010 Apr; 43(2):163-7. PubMed ID: 20457435
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular epidemiology of multiresistant Escherichia coli isolates from community-onset urinary tract infections in Cornwall, England.
    Woodford N; Kaufmann ME; Karisik E; Hartley JW
    J Antimicrob Chemother; 2007 Jan; 59(1):106-9. PubMed ID: 17090553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
    Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
    J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals.
    Ensor VM; Shahid M; Evans JT; Hawkey PM
    J Antimicrob Chemother; 2006 Dec; 58(6):1260-3. PubMed ID: 17071956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions.
    Oteo J; Navarro C; Cercenado E; Delgado-Iribarren A; Wilhelmi I; Orden B; García C; Miguelañez S; Pérez-Vázquez M; García-Cobos S; Aracil B; Bautista V; Campos J
    J Clin Microbiol; 2006 Jul; 44(7):2359-66. PubMed ID: 16825350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran.
    Mehrgan H; Rahbar M
    Int J Antimicrob Agents; 2008 Feb; 31(2):147-51. PubMed ID: 18060745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nosocomial outbreak of CTX-M-15-producing E. coli in Norway.
    Naseer U; Natås OB; Haldorsen BC; Bue B; Grundt H; Walsh TR; Sundsfjord A
    APMIS; 2007 Feb; 115(2):120-6. PubMed ID: 17295678
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15.
    Yumuk Z; Afacan G; Nicolas-Chanoine MH; Sotto A; Lavigne JP
    J Antimicrob Chemother; 2008 Aug; 62(2):284-8. PubMed ID: 18453527
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Activity of 9 beta-lactam antibiotics combined with clavulanic acid or sulbactam against the strains of broad-spectrum beta-lactamase (CTX-1) producing Enterobacteriaceae isolated at the Henri Mondor Hospital].
    Legrand P; Soussy CJ; Orsoni A; Brickley X; Duval J
    Pathol Biol (Paris); 1988 May; 36(5):425-9. PubMed ID: 3043338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
    Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
    Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
    Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.